Details
Stereochemistry | EPIMERIC |
Molecular Formula | C18H18N6O5S2.C3H8O2 |
Molecular Weight | 538.597 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 3 / 4 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(O)CO.[H][C@]12SCC(CSC3=CN=NN3)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C4=CC=C(O)C=C4)C(O)=O
InChI
InChIKey=CKOIKOHDEYTLFR-PFBPGKLMSA-N
InChI=1S/C18H18N6O5S2.C3H8O2/c19-12(8-1-3-10(25)4-2-8)15(26)21-13-16(27)24-14(18(28)29)9(7-31-17(13)24)6-30-11-5-20-23-22-11;1-3(5)2-4/h1-5,12-13,17,25H,6-7,19H2,(H,21,26)(H,28,29)(H,20,22,23);3-5H,2H2,1H3/t12-,13-,17-;/m1./s1
DescriptionCurator's Comment: Description was created based on several sources, including https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=NCI_Thesaurus&code=C81027 and http://www.ncbi.nlm.nih.gov/pubmed/426514
Curator's Comment: Description was created based on several sources, including https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=NCI_Thesaurus&code=C81027 and http://www.ncbi.nlm.nih.gov/pubmed/426514
Cefatrizine is a broad-spectrum, semisynthetic, first-generation cephalosporin with antibacterial activity. Cefatrizine binds to and inactivates penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. PBPs are enzymes involved in the terminal stages of assembling the bacterial cell wall and in reshaping the cell wall during growth and division. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis. Cefatrizine is used to treat a large variety of bacterial infections, such as respiratory tract, ear, skin and urinary tract infections. Cefatrizine is less effective against gram positive bacteria than first generation drugs. Antibiotics require constant drug level in body for therapeutic effect.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL5026 Sources: http://www.ncbi.nlm.nih.gov/pubmed/26776155 |
|||
Target ID: Bacterial growth Sources: http://www.ncbi.nlm.nih.gov/pubmed/1137381 |
|||
Target ID: map00550 Sources: http://www.kegg.jp/dbget-bin/www_bget?D02406 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | Unknown Approved UseUnknown |
|||
Curative | Unknown Approved UseUnknown |
|||
Curative | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Retrospective analysis of drug-induced urticaria and angioedema: a survey of 2287 patients. | 2001 Nov |
|
Pharmacokinetics of oral cefatrizine in pregnant and non-pregnant women with reference to fetal distribution. | 2007 |
|
Synthesis, characterization, antibacterial and anti-inflammatory activities of enoxacin metal complexes. | 2009 |
|
Pathogen incidence and antibiotic resistance patterns of catheter-associated urinary tract infection in children. | 2009 Dec |
|
Antibiotic Treatment of Dogs and Cats during Pregnancy. | 2010 Dec 14 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://en.pharmacodia.com/web/drug/1_10470.html
Curator's Comment: Can also be administered i.v. http://www.ncbi.nlm.nih.gov/pubmed/6660858
It is given by mouth as the base or, more commonly, as a compound with propylene glycol, in usual doses equivalent to 500 mg twice daily of cefatrizine.
Route of Administration:
Oral
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/426514
Curator's Comment: Bacterial isolates were from urine, sputum, throat, stool, and wound cultures of
patients. Cefatrizine inhibited the majority of Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, and Salmonella at concentrations below 12.5 mug/ml.
A total of 90% of isolates were inhibited by 1.6 ug of cefatrizine per ml
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C357
Created by
admin on Fri Dec 15 18:57:13 GMT 2023 , Edited by admin on Fri Dec 15 18:57:13 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID00972733
Created by
admin on Fri Dec 15 18:57:13 GMT 2023 , Edited by admin on Fri Dec 15 18:57:13 GMT 2023
|
PRIMARY | |||
|
57235-40-2
Created by
admin on Fri Dec 15 18:57:13 GMT 2023 , Edited by admin on Fri Dec 15 18:57:13 GMT 2023
|
NON-SPECIFIC STOICHIOMETRY | |||
|
100000091867
Created by
admin on Fri Dec 15 18:57:13 GMT 2023 , Edited by admin on Fri Dec 15 18:57:13 GMT 2023
|
PRIMARY | |||
|
SUB11797MIG
Created by
admin on Fri Dec 15 18:57:13 GMT 2023 , Edited by admin on Fri Dec 15 18:57:13 GMT 2023
|
PRIMARY | |||
|
64217-62-5
Created by
admin on Fri Dec 15 18:57:13 GMT 2023 , Edited by admin on Fri Dec 15 18:57:13 GMT 2023
|
PRIMARY | |||
|
6410757
Created by
admin on Fri Dec 15 18:57:13 GMT 2023 , Edited by admin on Fri Dec 15 18:57:13 GMT 2023
|
PRIMARY | |||
|
3731IA5GI9
Created by
admin on Fri Dec 15 18:57:13 GMT 2023 , Edited by admin on Fri Dec 15 18:57:13 GMT 2023
|
PRIMARY | |||
|
m3187
Created by
admin on Fri Dec 15 18:57:13 GMT 2023 , Edited by admin on Fri Dec 15 18:57:13 GMT 2023
|
PRIMARY | Merck Index | ||
|
C98215
Created by
admin on Fri Dec 15 18:57:13 GMT 2023 , Edited by admin on Fri Dec 15 18:57:13 GMT 2023
|
PRIMARY | |||
|
260-642-4
Created by
admin on Fri Dec 15 18:57:13 GMT 2023 , Edited by admin on Fri Dec 15 18:57:13 GMT 2023
|
PRIMARY | |||
|
CHEMBL286398
Created by
admin on Fri Dec 15 18:57:13 GMT 2023 , Edited by admin on Fri Dec 15 18:57:13 GMT 2023
|
PRIMARY | |||
|
DBSALT002708
Created by
admin on Fri Dec 15 18:57:13 GMT 2023 , Edited by admin on Fri Dec 15 18:57:13 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD